Log In
BCIQ
Print this Print this
 

Ondansetron lingual spray (Zensana) (BA-029)

  Manage Alerts
Collapse Summary General Information
Company Suda Ltd.
DescriptionOndansetron lingual spray
Molecular Target Serotonin (5-HT3) receptor
Mechanism of ActionSerotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy- and radiation-induced and post-operative nausea and vomiting (PONV); Prevent nausea and vomiting associated with chemotherapy and radiotherapy as well as post-operative induced nausea and vomiting; Treat chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation
PartnerOnxeo S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1.8M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/07/2013

$1.8M

Undisclosed

Undisclosed

Get a free BioCentury trial today